Literature DB >> 7215417

Pharmacokinetics of oral timolol studied by mass fragmentography.

J B Fourtillan, P Courtois, M A Lefebvre, J Girault.   

Abstract

The pharmacokinetics of timolol, after oral administration of single 20 mg doses to healthy subjects, has been studied using an original electron beam ionization GLC-mass spectrometry technique with computer -- controlled multiple ion detection. This method of mass fragmentography, tested with propranolol as an internal standard, permitted the measurement of timolol concentrations as low as 1 ng/ml with good precision and accuracy. It enabled the plasma level to be followed up to the twelfth hour after treatment. Individual variation was observed in bioavailability; the peaks plasma concentration (Cmax) of 50 to 103 ng/ml being achieved at different times(0.5--3h). The residual level after 12 h differed greatly between the subjects (0.8 to 7.2 ng/ml). The mean half-life of the terminal elimination phase was 2.62 +/- 0.17 h. Extra-renal elimination (metabolic and biliary) represented the main route of elimination, with a renal to body clearance ratio of 0.123. This level paralleled the percentage of unaltered timolol excreted in urine 24 h after its administration.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7215417     DOI: 10.1007/bf00561948

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  8 in total

1.  Physiological disposition and metabolism of timolol in man and laboratory animals.

Authors:  D J Tocco; A E Duncan; F A Delauna; H B Hucker; V F Gruber; W J Vandenheuvel
Journal:  Drug Metab Dispos       Date:  1975 Sep-Oct       Impact factor: 3.922

2.  IGPHARM: interactive graphic package for pharmacokinetic analysis.

Authors:  C Gomeni; R Gomeni
Journal:  Comput Biomed Res       Date:  1978-08

3.  The disposition of timolol in man.

Authors:  P Vermeij; M el-Sherbini-Schepers; P A van Zwieten
Journal:  J Pharm Pharmacol       Date:  1978-01       Impact factor: 3.765

4.  Clinical pharmacokinetics of atenolol.

Authors:  J McAinsh
Journal:  Postgrad Med J       Date:  1977       Impact factor: 2.401

5.  Plasma timolol levels after oral and intravenous administration.

Authors:  O F Else; H Sorenson; I R Edwards
Journal:  Eur J Clin Pharmacol       Date:  1978-12-18       Impact factor: 2.953

6.  Acebutolol metabolite plasma concentration during chronic oral therapy.

Authors:  R A Winkle; P J Meffin; W B Ricks; D C Harrison
Journal:  Br J Clin Pharmacol       Date:  1977-10       Impact factor: 4.335

7.  Human pharmacokinetic and pharmacodynamic studies on the atenolo (ICI 66,082), a new cardioselective beta-adrenoceptor blocking drug.

Authors:  F J Conway; J D Fitzgerald; J McAinsh; D J Rowlands; W T Simpson
Journal:  Br J Clin Pharmacol       Date:  1976-04       Impact factor: 4.335

8.  Timolol kinetics in chronic renal insufficiency.

Authors:  D T Lowenthal; J M Pitone; M B Affrime; J Shirk; P Busby; K E Kim; J Nancarrow; C D Swartz; G Onesti
Journal:  Clin Pharmacol Ther       Date:  1978-05       Impact factor: 6.875

  8 in total
  3 in total

Review 1.  Neuropsychiatric Adverse Events from Topical Ophthalmic Timolol.

Authors:  Nevio Cimolai
Journal:  Clin Med Res       Date:  2019-08-28

2.  The pharmacokinetics of timegadine and two of its metabolites after multiple oral dosing, and the effects of concomitant administration of ibuprofen.

Authors:  S George; A McBurney; J W Ward
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 3.  Timolol 0.1% in Glaucomatous Patients: Efficacy, Tolerance, and Quality of Life.

Authors:  Letizia Negri; Antonio Ferreras; Michele Iester
Journal:  J Ophthalmol       Date:  2019-05-02       Impact factor: 1.909

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.